ICML Update: Lenalidomide and Rituximab Are Well Tolerated and Effective in Patients with Previously Untreated Follicular Lymphoma

On June 20, at the 12th International Conference on Malignant Lymphoma, Dr. Peter Martin presented preliminary results from the CALGB-sponsored phase II study of oral lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Although preliminary, the overall and complete response rates were promising (93% and 72%, respectively) and the regimen was well tolerated. Moreover, these results are comparable to standard chemotherapy-containing regimens and provide rationale for further development of non-chemotherapy treatments for patients with follicular lymphoma. Shortly we will begin conducting a trial of lenalidomide, rituximab, and ibrutinib in patients with previously untreated follicular lymphoma and hope to improve even further on these results.

Please look back to this space for further updates regarding future trials with lenalidomide, rituximab, and ibrutinib.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: